-
NHS: Relapsing-remitting multiple sclerosis (RRMS) patients with active disease may now be treated with Ocrevus
Relapsing-remitting multiple sclerosis (RRMS) patients with active disease may now be treated with Ocrevus (ocrelizumab, developed by Genentech) within the National Health Service (NHS) — the subsidized public health system that covers England and Wales.
Specifically, the National Institute for Health and Care Excellence, known as NICE, recommended that Ocrevus be included among the treatments provided RRMS patients. Eligible patients are those experiencing relapses or with brain imaging evidence (on an MRI) of new areas of disease activity, and who are unable or unwilling to be treated with Lemtrada (alemtuzumab, Sanofi Genzyme).
Click here to read more: NICE Agrees to Add Ocrevus to NHS as Treatment for RRMS Patients with Active Disease
What do you think about this news? Does it apply to you? Do you have access to this treatment where you live?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.